Phase 2 study of pembrolizumab in patients with recurrent & residual high-grade meningiomas|CellTalk скачать в хорошем качестве

Phase 2 study of pembrolizumab in patients with recurrent & residual high-grade meningiomas|CellTalk

Meningiomas are the most prevalent primary central nervous system tumor, with a prevalence of 170,000 cases in the United States. Maximal safe resection is the cornerstone of meningioma treatment, and adjuvant radiation may sometimes be necessary. Due to the lack of effective systemic therapies, there are limited options for additional therapies, especially for recurrent or higher-grade meningiomas. Recent studies suggest, targeting the immunological microenvironment may be a promising meningioma treatment. The authors consequently proposed that pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, would have antitumor activity for high-grade meningiomas. The authors have designed a prospective phase-2 study investigating pembrolizumab in patients with progressive high-grade meningiomas using a dosage schedule that has proven effective in systemic cancers. Read more (https://www.celltalk.org/yogita-dhas-...) #Meningiomas #BrainTumor #Meningioma #Meninges #MeningiomaCauses #MeningiomaTumor #MeningiomaSurgery #MeningiomaTypes #MeningiomaICD10 #MeningiomaBrain #pembrolizumab #MeningiomaHeadaches #India #CellTalk #LifeScinces #Journal #HealthJournal #JournalClub #Healthcare #YouTube #SocialMedia #YouTube For more interesting videos --------------------------------------------- Subscribe to CellTalk:    / @celltalk8633   You may also like to watch:    • A hybrid CNN-GLCM classifier for detection...   Connect with us on social: --------------------------------------------- LinkedIn:   / celltalk   Facebook:   / celltalk-101057335993489   Visit CellTalk: https://www.celltalk.org/